Dyne Therapeutics, Inc.

Contributing Author

Recent Articles by Dyne Therapeutics, Inc.

3 hours	Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights DYN +5.50% GlobeNewswire
Apr-27	Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE Platform at 2026 ASGCT Annual Meeting DYN GlobeNewswire
Apr-23	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DYN GlobeNewswire
Apr-01	Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines DYN GlobeNewswire
Mar-08	Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) DYN GlobeNewswire
Mar-08	Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) DYN GlobeNewswire
Mar-02	Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights DYN GlobeNewswire
Feb-25	Dyne Therapeutics to Participate in Upcoming Investor Conferences DYN GlobeNewswire
Feb-22	Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference DYN GlobeNewswire
Jan-20	Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 DYN GlobeNewswire
Jan-07	Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference DYN +7.01% GlobeNewswire
Dec-23	Dyne Therapeutics Appoints Vikram Karnani to Board of Directors DYN GlobeNewswire
Dec-11	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares DYN GlobeNewswire
Dec-09	Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock DYN +6.78% GlobeNewswire
Dec-08	Dyne Therapeutics Announces Proposed Public Offering of Common Stock DYN +9.47% GlobeNewswire
Dec-08	Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) DYN +9.47% GlobeNewswire
Dec-07	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET DYN GlobeNewswire
Nov-05	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights DYN -12.89% DYN GlobeNewswire
Nov-03	Dyne Therapeutics to Present at Upcoming Investor Conferences DYN +6.78% GlobeNewswire
Oct-06	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) DYN +10.28% DYN GlobeNewswire
Oct-02	Dyne Therapeutics Appoints Brian Posner to its Board of Directors DYN GlobeNewswire
Sep-29	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy DYN -5.93% GlobeNewswire
Aug-27	Dyne Therapeutics to Present at Upcoming Investor Conferences DYN GlobeNewswire
Aug-04	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) DYN GlobeNewswire
Jul-28	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights DYN -6.43% GlobeNewswire
Jul-02	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares DYN GlobeNewswire
Jun-30	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock DYN -8.82% GlobeNewswire
Jun-30	Dyne Therapeutics Announces Proposed Public Offering of Common Stock DYN -8.82% DYN GlobeNewswire
Jun-30	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital DYN -8.82% DYN GlobeNewswire
Jun-17	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting DYN -21.42% GlobeNewswire
Jun-16	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET DYN GlobeNewswire
Jun-05	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress DYN GlobeNewswire
May-08	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights DYN +20.16% GlobeNewswire

Dyne Therapeutics, Inc.

Recent Articles by Dyne Therapeutics, Inc.

Upgrade your Finviz experience